![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Use of Ledipasvir/Sofosbuvir Fixed Dose Combination for Treatment of HCV Genotype-1 Infection in Patients Coinfected with HIV - Eradicate Study
|
|
|
Reported by Jules Levin
AASLD 2014 Nov 9
Anu Osinusi1,2, Kerry Townsend1,2, Amy Nelson1,2, Anita Kohli3,4, Eric Meissner1, Chloe Gross3, Michael A. Polis1, Phil S Pang5, William T. Symonds5, Mohammed M. Sajadi1, John Hogan6, G. Mani Subramanian5, John G. McHutchison5, Henry Masur4, Shyam Kottilil1,2 for the NIAID/CC Hepatitis C ERADICATE team1,3,4
1Laboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland, 2Dept of Infectious Diseases, University of Maryland, Baltimore, 3Leidos /SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, Maryland , 4Critical Care Medicine Department, NIH, Bethesda, Maryland , 5Gilead Sciences, Foster City, California, 6Unity Health Care Inc, Washington DC
![AASLD1.gif](../images/111014/111014-1/AASLD1.gif)
![AASLD2.gif](../images/111014/111014-1/AASLD2.gif)
![AASLD3.gif](../images/111014/111014-1/AASLD3.gif)
![AASLD4.gif](../images/111014/111014-1/AASLD4.gif)
![AASLD5.gif](../images/111014/111014-1/AASLD5.gif)
![AASLD6.gif](../images/111014/111014-1/AASLD6.gif)
![AASLD7.gif](../images/111014/111014-1/AASLD7.gif)
![AASLD8.gif](../images/111014/111014-1/AASLD8.gif)
![AASLD9.gif](../images/111014/111014-1/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|